Evidence map›Paper›PMID 40676760›Full record

ArticleThe Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics2025

Rupturing the Temporality of Pharmaceutical Patents: A Sketch for a New Temporal Economy of Pharmaceutical Markets.

Susi Geiger

Abstract read
In one paragraph

Article in The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Susi Geigerhttps://ror.org/05m7pjf47College of Business, University College Dublin, Ireland.ORCID 0000-0002-2400-7333

Funding

European Research Council 771217
6 · The paper itself

Abstract

The objective of this paper is to devise a set of principles and practices that can break with the temporalities of current pharmaceutical markets, and on this basis sketch a social contract for a new (temporal) political economy of pharmaceuticals. Pharmaceutical futures are, in my analysis, doubly predetermined by standard arguments around pharmaceutical patenting and pricing: they are narrated as a consequence of "past" investments to be recouped, but they are also predetermined on a particular "future perfect," where past investment successes and promises to maintain the status quo determine the course of action of future investors. This double colonization of the future, in my analysis, eliminates any scope for meaningful change. Making this often implicit temporality of pharmaceutical markets explicit may allow to better take into account multiple temporalities in regulating this space. Chiefly among them are patients' temporalities, which typically get overridden by the peculiar timelines of patent-based markets. The mRNA vaccine market serves as an illustration of the theoretical arguments raised, and I discuss four strategies that could lead toward a new temporal political economy of pharmaceutical markets: temporally sensitive policymaking; decolonizing the future through narrower patents; delinking patents from their asset condition; and pharmaceutical commons.

Indexed as

Drug IndustryPatents as TopicHumansPoliticsUnited StatesdelinkagefuturemRNA technologypatentspharmaceutical assetpharmaceutical commonspharmaceutical marketspolitical economy of pharmaceuticalstemporalitytemporal policymaking

Identifiers

PMID40676760
PMCPMC12912826

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.